Kyverna Therapeutics Reports Positive Phase 2 Trial Results
I'm PortAI, I can summarize articles.
Kyverna Therapeutics announced positive Phase 2 trial results for mivocabtagene autoleucel (miv-cel) in treating stiff person syndrome, showing significant clinical benefits and no high-grade adverse effects. This positions miv-cel as a potential first FDA-approved CAR T-cell therapy for autoimmune diseases. Despite the positive trial, Kyverna faces financial challenges, with consistent losses and zero revenue, impacting its stock performance. The latest analyst rating is a Buy with a $25.00 price target, but Spark's AI Analyst rates it as Underperform due to financial difficulties.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments